Dashboard
Manage Tickers

CDXCChromaDex Corp.

Nasdaq chromadex.com


$ 3.43 $ 0.00 (0 %)    

Thursday, 12-Sep-2024 11:54:29 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.73 $ 0.10 (0.02 %)
DIA $ 408.72 $ -0.74 (-0.18 %)
SPY $ 554.44 $ -0.55 (-0.1 %)
TLT $ 100.13 $ -0.24 (-0.24 %)
GLD $ 235.90 $ 1.26 (0.54 %)
$ 3.32
$ 3.43
-- x --
$ 3.45 x 300
$ 3.43 - $ 3.43
$ 1.25 - $ 4.65
374,579
na
252.1M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-14-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-18-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-15-2018 12-30-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-10-2017 07-01-2017 10-Q
30 05-11-2017 04-01-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-10-2016 10-01-2016 10-Q
33 08-11-2016 07-02-2016 10-Q
34 05-12-2016 04-02-2016 10-Q
35 03-17-2016 01-02-2016 10-K
36 11-12-2015 10-03-2015 10-Q
37 08-13-2015 07-04-2015 10-Q
38 05-14-2015 04-04-2015 10-Q
39 03-19-2015 01-03-2015 10-K
40 11-06-2014 09-27-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chromadex-expands-distribution-of-niagen-iv-and-injections-to-14-new-wellness-clinics-wells-pharma-to-compound-and-distribute-pharmaceutical-grade-niagen-following-successful-initial-launch
ChromaDex Expands Distribution Of Niagen+ ...
09/10/2024 12:35:32

chromadex-granted--us-patent-number-10000520-c1-covering-the-composition-of-matter-for-the-disodium-salt-of-nmnh
ChromaDex Granted U.S. Patent Number 10,0...
08/19/2024 12:33:54

hc-wainwright--co-reiterates-buy-on-chromadex-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Chro...
08/09/2024 21:30:40

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

chromadex-now-expects-fy24-revenue-growth-of-10---15--yy
ChromaDex Now Expects FY24 Revenue Growth ...
08/07/2024 21:41:18

Prior guidance: "Looking forward, for the full year, the Company expects the trajectory of full year revenue growth to cont...

chromadex-q2-sales-22739m-miss-23437m-estimate
ChromaDex Q2 Sales $22.739M Miss $23.437M ...
08/07/2024 20:54:11

ChromaDex (NASDAQ:CDXC) reported quarterly sales of $22.739 million which missed the analyst consensus estimate of $23.437 mill...

chromadex-launches-niagen-nad-test-kit-available-exclusively-to-health-care-practitioners
ChromaDex Launches Niagen+ NAD+ Test Kit A...
07/23/2024 12:38:05

Results from the at-home test kit are available to HCPs and their patients through 1healthChromaDex Corp. (NASDAQ:CDXC), the gl...

chromadex-says-board-appointed-james-lee-as-interim-cfo
Chromadex Says Board Appointed James Lee A...
07/16/2024 20:15:24

-SEC Filing

chromadex-to-ship-pharmaceutical-grade-intravenous-and-injectable-niagen-at-wellness-clinics-in-august
ChromaDex To Ship Pharmaceutical-Grade Int...
07/16/2024 12:38:59

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide ribos...

hc-wainwright--co-reiterates-buy-on-chromadex-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Chro...
07/15/2024 10:40:09

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

chromadex-joins-russell-2000-index-as-part-of-annual-reconstitution-inclusion-effective-july-1-2024
ChromaDex Joins Russell 2000 Index As Part...
07/01/2024 12:34:20

milestone-phase-ii-clinical-study-demonstrates-niagen-patented-nicotinamide-riboside-to-improve-functional-mobility-for-individuals-with-peripheral-artery-disease
Milestone Phase II Clinical Study Demonstr...
06/24/2024 12:38:04

NR improved the six-minute walking distance and treadmill walking time for those with PAD

chromadex-unveils-niagen-with-fda-authorization-nrc-to-be-available-in-iv-shot-and-push-forms-at-clinics-nationwide
ChromaDex Unveils Niagen+ With FDA Authori...
06/13/2024 12:34:22

roth-mkm-maintains-buy-on-chromadex-maintains-6-price-target
Roth MKM Maintains Buy on ChromaDex, Maint...
06/12/2024 15:46:32

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

why-gamestop-shares-are-trading-lower-by-over-22-here-are-other-stocks-moving-in-fridays-mid-day-session
Why GameStop Shares Are Trading Lower By O...
06/07/2024 17:07:30

chromadex-announces-fda-orphan-drug-and-rare-pediatric-disease-designations-for-nrc-in-treatment-of-ataxia-telangiectasia-at
ChromaDex Announces FDA Orphan Drug And Ra...
06/07/2024 12:34:58

chromadex-gets-orphan-designation-status-from-fda-for-nicotinamide-riboside-chloride-for-treatment-of-ataxia-telangiectasia
ChromaDex Gets Orphan Designation Status F...
06/03/2024 15:51:16

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624

hc-wainwright--co-reiterates-buy-on-chromadex-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Chro...
05/09/2024 11:25:07

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/08/2024 20:31:13

chromadex-q1-2024-adj-eps-001-beats-002-estimate-sales-22200m-miss-23970m-estimate
ChromaDex Q1 2024 Adj EPS $(0.01) Beats $(...
05/08/2024 20:05:35

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by ...

chromadex-announces-ingredient-partnership-with-solgar-solgar-cellular-nutrition-cellular-energy-features-niagen-to-support-nad-levels-for-cellular-health
ChromaDex Announces Ingredient Partnership...
04/30/2024 12:35:04

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION